# Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck

> **NCT00570674** · PHASE1,PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 29 (actual)

## Conditions studied

- Squamous Cell Carcinoma of the Head and Neck
- Basaloid Squamous Cell Carcinoma
- Undifferentiated Carcinoma
- Adenosquamous Cell Carcinoma

## Interventions

- **DRUG:** Abraxane
- **DRUG:** Erbitux
- **DRUG:** Carboplatin
- **RADIATION:** Intensity Modulated Radiation Therapy

## Key facts

- **NCT ID:** NCT00570674
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** The study did not continue to phase II due to the importance of HPV status as a prognostic factor to guide treatment decisions.
- **Last updated:** 2017-11-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00570674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00570674, "Abraxane in Combination With Carboplatin, Erbitux and IMRT for Locally Advanced Squamous Cancer of the Head and Neck". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00570674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*